Compare CSPI & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSPI | RNXT |
|---|---|---|
| Founded | 1968 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.6M | 79.4M |
| IPO Year | 1994 | 2021 |
| Metric | CSPI | RNXT |
|---|---|---|
| Price | $7.50 | $1.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.13 |
| AVG Volume (30 Days) | 8.1K | ★ 484.7K |
| Earning Date | 08-14-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 75.00 | 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,730,000.00 | $1,123,000.00 |
| Revenue This Year | N/A | $244.84 |
| Revenue Next Year | N/A | $195.26 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 6.36 | ★ 2511.63 |
| 52 Week Low | $7.11 | $0.70 |
| 52 Week High | $15.00 | $2.59 |
| Indicator | CSPI | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 47.25 | 40.59 |
| Support Level | $7.39 | $0.83 |
| Resistance Level | $8.21 | $1.30 |
| Average True Range (ATR) | 0.31 | 0.10 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 22.67 | 28.85 |
CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.